Your browser doesn't support javascript.
loading
Effectiveness of the female condom in preventing HIV and sexually transmitted infections: a systematic review and meta-analysis.
Wiyeh, Alison B; Mome, Ruth K B; Mahasha, Phetole W; Kongnyuy, Eugene J; Wiysonge, Charles S.
Afiliação
  • Wiyeh AB; Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa. wberiliy@yahoo.co.uk.
  • Mome RKB; Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA. wberiliy@yahoo.co.uk.
  • Mahasha PW; Ottumwa Regional Health Center, 1001 Pennsylvania Avenue, Ottumwa, IA, 52501, USA.
  • Kongnyuy EJ; Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa.
  • Wiysonge CS; Grants, Innovation and Product Development, South African Medical Research Council, Cape Town, South Africa.
BMC Public Health ; 20(1): 319, 2020 Mar 12.
Article em En | MEDLINE | ID: mdl-32164652
ABSTRACT

BACKGROUND:

The effectiveness of female condoms for preventing HIV and sexually transmitted infections (STIs) remains inconclusive. We examined the effects of female condoms on the acquisition of HIV and STIs.

METHODS:

We searched four databases, two trial registries, and reference lists of relevant publications in October 2018 and updated our search in February 2020. We screened search output, evaluated study eligibility, and extracted data in duplicate; resolving differences through discussion. We calculated the effective sample size of cluster randomised trials using an intra-cluster correlation coefficient of 0·03. Data from similar studies were combined in a meta-analysis. We performed a non-inferiority analysis of new condoms relative to marketed ones using a non-inferiority margin of 3%. We assessed the certainty of evidence using GRADE.

RESULTS:

We included fifteen studies of 6921 women. We found that polyurethane female condoms (FC1) plus male condoms may be as effective as male condoms only in reducing HIV acquisition (1 trial, n = 149 women, RR 0.07, 95%CI 0.00-1.38; low-certainty evidence). However, the use of FC1 plus male condoms is superior to male condoms alone in reducing the acquisition of gonorrhoea (2 trials, n = 790, RR 0.59, 95%CI 0.41-0.86; high-certainty evidence) and chlamydia (2 trials, n = 790, RR 0.67, 95%CI 0.47-0.94; high-certainty evidence). Adverse events and failure rates of FC1 were very low and decreased during follow up. Although the functionality of newer female condoms (Woman's, Cupid, Pheonurse, Velvet, and Reddy) may be non-inferior to FC2, there were no available studies assessing their efficacy in preventing HIV and STIs.

CONCLUSION:

The use of female plus male condoms is more effective than use of male condoms only in preventing STIs and may be as effective as the male condom only in preventing HIV. There is a need for well conducted studies assessing the effects of newer female condoms on HIV and STIs. PROSPERO REGISTRATION NUMBER CRD42018090710.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Sexualmente Transmissíveis / Infecções por HIV Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Sexualmente Transmissíveis / Infecções por HIV Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article